Pentostatin (2′-deoxycoformycin) in the treatment of cutaneous T-cell lymphoma
- 30 June 1997
- journal article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 36 (6) , 950-955
- https://doi.org/10.1016/s0190-9622(97)80279-4
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- The purine analogs--a therapeutic beauty contest.Journal of Clinical Oncology, 1992
- Pentostatin (2′-deoxycoformycin) for the treatment of lymphoid neoplasmsCancer Treatment Reviews, 1990
- A Randomized Trial Comparing Combination Electron-Beam Radiation and Chemotherapy with Topical Therapy in the Initial Treatment of Mycosis FungoidesNew England Journal of Medicine, 1989
- 2′-Deoxycoformycin (Pentostatin) for Lymphoid MalignanciesAnnals of Internal Medicine, 1988
- Biochemical consequences of 2′-deoxycoformycin treatment in a patient with T-cell lymphoma. Some unusual findingsCancer, 1987
- The role of pentostatin (2′-deoxycoformycin, dCF) in the management of lymphoproliferative malignanciesBlood Reviews, 1987
- Low-dose deoxycoformycin in lymphoid malignancy.Journal of Clinical Oncology, 1985
- An investigation of 2'-deoxycoformycin in the treatment of cutaneous T- cell lymphomaBlood, 1983
- Clinical pharmacology of deoxycoformycinBlood, 1981
- The biochemical and clinical consequences of 2'-deoxycoformycin in refractory lymphoproliferative malignancyBlood, 1981